Transparency
Changelog
This is a living resource, not a frozen one. Every substantive change to the content — what we added, updated, re-verified, or corrected — is logged here with a date, so you can judge how current and how maintained it is.
Evidence reviewed and current as of July 8, 2026
How we keep it current. Health information ages. We re-check pages against the latest randomized trials, FDA labels, and regulator statements; every evidence page carries its own “last reviewed” date and links its primary sources. When we get something wrong, we fix it in the open and note it below. We sell a book — never treatment, doses, or a source. More on our method →
A cleaner, faster site — and a fresh evidence scan
We rebuilt the site's look and layout to be calmer and quicker to use: the answer, the evidence grade, and the sources come first, with the decorative filler removed. We also re-scanned the latest GLP-1 news against our own graded pages. The takeaway: the library is current, and we held the line on a widely-shared 'tirzepatide is now approved for fatty liver (MASH)' claim — our evidence still shows semaglutide is the only GLP-1 FDA-approved for MASH, with tirzepatide's liver data still investigational. We update the moment that changes, not before.
See it →Per-drug guides for Ozempic, Wegovy, Mounjaro, and Zepbound
New brand-guide pages that answer the first question people have — what is this drug, actually? Each names the molecule (Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide), its FDA-approved use, its sibling brand, and then routes you to the graded, sourced answers on side effects, results, and the myths. No doses, no sourcing — every fact traces to the FDA label.
See it →Mounjaro vs. Zepbound: same molecule, two labels
A new page on one of the most-searched GLP-1 confusions: Mounjaro and Zepbound are both tirzepatide from Eli Lilly, but with different FDA-approved uses (diabetes vs. weight management and sleep apnea) — which is why insurance can treat them so differently, including under Medicare's temporary GLP-1 Bridge. Fact-checked against the FDA labels and CMS.
See it →The women's-health pages are now live: PCOS and menopause
The two deep, graded hubs on GLP-1 medicines in PCOS and in menopause — held back while they went through medical, legal, and fact-checking review — have cleared review and are now published. Each grades every sub-claim honestly, states the off-label status plainly, and separates what the evidence supports from where the hype runs ahead of it.
See it →"Ozempic face," rebuilt — and retatrutide's latest Phase 3 data
The "Ozempic face" page is expanded to answer what people actually ask: is it real, is it the drug or the weight loss, does it happen with Mounjaro and Zepbound too, is it permanent, and what dermatologists actually say — grounded in a 2025 systematic review. And the retatrutide page is refreshed with the pivotal TRIUMPH-1 result presented at ADA 2026 (28.3% average weight loss at the top dose), still framed honestly as conference-presented and not yet peer-reviewed.
See it →Five practical pages the search results get wrong
New evidence pages on the everyday questions where the top search results are mostly clinic and telehealth blogs: how long a GLP-1 stays in your system (half-life, and why side effects linger after stopping); periods and fertility, including the honest story behind “Ozempic babies”; loose skin after weight loss (which is caused by the weight loss, not the drug specifically); sleep — separating Zepbound's real, FDA-approved sleep-apnea benefit from the unproven “vivid dreams” claim; and how to travel with your pen (TSA rules and each product's storage limits). Each fact-checked against the FDA labels and primary research, and reviewed by a clinician and a legal reviewer.
See it →Two new tools: the Red-Flag Symptom Sorter and the Maintenance Navigator
The Red-Flag Symptom Sorter takes a GLP-1 side effect and shows the honest spectrum — what usually settles, what's worth raising at a visit, and the specific signs that mean don't wait — grounded in the FDA-label warnings. It routes you to care; it never diagnoses or judges your situation. The Maintenance Navigator is for the biggest un-served group: people who've hit their goal. It lays out what the evidence says about holding weight (on the medicine, a lower dose, or off it), the levers with the best evidence, and a personal drift early-warning band. Both run entirely on your device and give no doses. Reviewed by a clinician and a legal reviewer before launch.
See it →Three new evidence pages: the GLP-1 pill, fatty liver, and drug interactions
Oral semaglutide — the “GLP-1 pill” — now has its own page: what Rybelsus (diabetes) and the December-2025 oral weight-loss pill actually do, and why a pill isn't automatically “weaker” or “safer.” A new fatty-liver page explains Wegovy's August-2025 accelerated approval for MASH (the ESSENCE trial, and why “accelerated” is the whole story). And a drug-interactions guide answers “can I take X with my GLP-1?” — what the labels actually flag (birth control on tirzepatide, insulin, blood thinners) versus what's mostly theoretical. Each was fact-checked against primary sources, and reviewed by a clinician and a legal reviewer.
See it →Redesigned the Evidence Library and home page for clearer reading
The Evidence Library was one long wall of identical cards; now each topic leads with a featured answer and drops to compact, scannable rows, so you can find the right page faster. The home page and card excerpts are trimmed so nothing reads as a text wall on a phone. Also new: a visible “last reviewed” freshness marker on every evidence page, and gentle motion that respects reduced-motion settings.
See it →Five new myth-vs-evidence answers on the 2026 headlines
The Myth vs Evidence library grew to 60 graded answers, tackling claims that are circulating right now: “tirzepatide is FDA-approved for fatty liver” (false — it's semaglutide that's approved for MASH; tirzepatide is still investigational), “GLP-1s cure alcoholism/addiction” (a real early trial signal, not a cure, not approved), “you can just stop once you hit goal weight” (mostly false — the STEP 1 extension showed most weight returns within a year), “the pill works exactly like the shot” (depends which pill), and “GLP-1s give you diabetes” (false — they treat and help prevent it). Each fact-checked against primary sources and graded on the Evidence Ladder.
See it →New: “GLP-1 by the numbers” — the key statistics, each honestly sourced
A single reference page for the figures people actually search — average weight loss by drug (tirzepatide ~21%, oral semaglutide ~16–17%, semaglutide ~15%, orforglipron ~11%, investigational retatrutide ~28% topline), the odds of hitting each milestone, how common the side effects are vs placebo (nausea 44% vs 16%…), the serious-but-uncommon risks, the ~20% cardiovascular benefit (relative), regain after stopping (~two-thirds in a year), and the insurance-appeal odds — laid out in clean tables with every number tied to its primary source and labeled by evidence strength (RCT / label / observational / topline-investigational). Fact-checked number by number; framing reviewed so it reads as an honest ledger, not a hype or scare sheet.
See it →Denied coverage for a GLP-1? A new section on how to appeal — and why it's worth it
The cost & access page now has a practical 'What if you're denied? How to appeal' section, built around a striking, verified fact: in Medicare Advantage in 2024, only about 11.5% of denied prior-authorization requests were appealed — but about 80% of the appeals that were filed got overturned (KFF). Most people never appeal; most who do, win. It lays out the steps (get the denial in writing, have your prescriber document the criteria, use the internal and external appeal levels), with honest caveats that success varies by plan type (Medicaid managed-care appeals succeed far less often) and that it's not a guarantee. Fact-checked against KFF and legally reviewed.
See it →New page: Missed a GLP-1 dose? What each medicine's label says
One of the most-asked practical questions, answered straight from the FDA labels — because the rules genuinely differ by product. Ozempic's label says take a missed weekly dose within 5 days; Wegovy's says only if your next dose is more than 2 days away; Mounjaro and Zepbound say within 4 days (96 hours) — after the window, skip it and resume your normal day. The catch we spell out: Ozempic and Wegovy are the same drug (semaglutide) but have different windows, which trips people up. Plus a plain worked example for Wegovy's confusing rule, why you should never double up, the extra blood-sugar angle if you also take insulin or a sulfonylurea, and what to do after a longer gap (don't restart your old dose on your own). Every number is quoted to the drug's own label and fact-checked; full board (fact-check, legal, clinician) + managing-editor GO.
See it →New page: GLP-1 and surgery — do you have to stop before an operation?
A new evidence page on a real safety question the internet gets wrong. GLP-1s slow the stomach, which matters for anesthesia — but the guidance changed: the 2023 “hold it before every procedure” advice was superseded in practice by a 2024 multi-society update where most people can continue, with the team individualizing. The page grades the science honestly (that GLP-1s leave more food in the stomach after fasting is established; that this causes more actual aspiration is not shown — a rare outcome, so “no harm shown yet,” not “no risk”), and lands the one universal, safe action: tell your surgical/anesthesia/endoscopy team in advance, and never stop — or hide — the medicine on your own. It also covers emergencies and warns against postponing a needed procedure out of fear. Full board (fact-check, clinician, legal) + managing-editor GO.
See it →New tool: “Which GLP-1?” — a neutral decision aid (it never picks for you)
A new on-device tool for the most-asked question of all: which one? Tick what matters to you — pill vs injection, type 2 diabetes, heart-risk reduction, sleep apnea, weight-loss goal, cost — and it shows how the FDA-approved options (semaglutide, tirzepatide, orforglipron) line up on that, then hands you a tailored list of questions to bring to your clinician. It deliberately does NOT recommend a drug: it highlights only what each option is approved or studied for, always shows the shared reality that all three commonly cause GI side effects (tolerability, not the average number, is usually what decides), and always surfaces the contraindication/pregnancy questions. Full board (legal, fact-check, clinician, hype-balance) + managing-editor GO.
See it →New page: the lesser-known & emerging GLP-1 side effects, each graded honestly
A new evidence page tackles the rarer and newer side-effect signals people ask about most — the eye condition NAION, gallbladder problems, mood and suicidality, fertility/cycle changes, and feeling cold — and grades each ONE ON ITS OWN evidence, from established (gallbladder) to purely anecdotal (temperature). The point is to let you tell a documented risk from a viral worry. It's the honest, non-selling counterpart to the noise: NAION is taken seriously by the WHO/EU but is rare and unproven and the US label hasn't added it; the old depression/suicide alarm has, after review, not held up; and it says plainly which few signs (sudden vision loss, gallbladder attack with fever/jaundice, thoughts of self-harm) mean seek care now. Went through the full board — fact-check, clinician, hype-balance, legal — and a managing-editor GO.
See it →Side-effect pages now show how common each effect really was — vs placebo
The nausea, vomiting, fatigue, dizziness, reflux/heartburn and burping pages now open with a small 'how often, in the trial' chart: the rate reported ON the medicine next to the rate on PLACEBO (e.g. nausea 44% vs 16%). Showing the placebo baseline is the honest part — it's the gap that's attributable to the drug, and a reminder that some of every symptom happens on a sugar pill too. Every number is taken straight from the FDA Wegovy label and fact-checked; the chart makes clear it's how OFTEN each was reported, not how severe.
See it →New tool — “Am I Normal?”, an honest weight-loss trajectory check
A new on-device tool: log your own weigh-ins and see how your weight loss compares to the STEP/SURMOUNT trial average AT THE SAME WEEK (not the finish line), plus an honest read on whether a flat stretch is everyday noise or a genuine plateau. Everything stays in your browser. It's deliberately a mirror, not a grade or a prediction — 'below the average' is framed as common, not failure; rapid loss and unexpected stalls are routed to your prescriber; and it never suggests changing a dose. Went through the full board (clinician, legal, fact-check) and a red-team read with a managing-editor GO.
See it →Two new side-effect deep-dives: heartburn/reflux and dizziness
Added graded, board-reviewed pages on two more GLP-1 side effects — heartburn and acid reflux, and dizziness and lightheadedness — each explaining why it happens, what actually helps, and the red-flag signs that mean get medical help. Both went through the full board (fact-check against the FDA labels on DailyMed, clinician safety review, legal/compliance, and a red-team read). The reflux page is honest that the slowed-emptying mechanism is the leading explanation rather than settled science (and that weight loss can ease reflux over time); the dizziness page adds a clearly-sourced low-blood-sugar first-aid section for readers who also take insulin or a sulfonylurea.
See it →New CagriSema page and five more myth answers from the mid-2026 research review
Published a graded page on CagriSema (the GLP-1 + amylin combination) and five new Myth-vs-Evidence answers drawn from the latest evidence — including the EVOKE finding that GLP-1s did NOT slow Alzheimer's, whether the new pill matches the injections, and what Medicare's new coverage does and doesn't do. All fact-checked, and clinician- and legally-reviewed where needed. We also refreshed the retatrutide page with its full phase-3 (TRIUMPH-1) data.
See it →Scanned the latest GLP-1 research and refreshed “What's new”
We reviewed the notable developments through mid-2026 — Medicare's new GLP-1 “Bridge” coverage and falling cash prices, retatrutide's full phase-3 data, the CagriSema (GLP-1 + amylin) results, and a useful negative (semaglutide did not slow Alzheimer's) — and added them to the news feed with sources.
See it →The Myth vs Evidence library grew to 50 graded answers
Added answers on hair loss, bone health, pancreatitis, kidney and heart effects, fertility, birth control, pregnancy, alcohol, and more — each graded on the 8-rung Evidence Ladder and linked to primary sources. Every one is checked against the underlying trial or FDA label before it goes live.
See it →Every FDA drug-label citation now opens on DailyMed
We moved our label references to the U.S. National Library of Medicine's DailyMed, so any reader — or search engine — can open and verify the current, official prescribing information directly, rather than a version-pinned PDF that can move or expire.
See it →Articles got a visual upgrade
The plain-language explainers now lead with numbered key takeaways and carry figures and comparison tables, so the evidence is easier to scan and share — without changing any of the underlying facts or grades.
See it →Fixed and clarified a handful of citations
Our review caught and corrected some source details before publication — including tightening how we describe the bone-density and hormone-therapy evidence — so the wording never runs ahead of what the cited study actually shows.
See it →The Evidence Library is now organized by topic
The graded pages are grouped into browsable clusters — choosing & comparing, side effects, nutrition & muscle, results & stopping, the medicines & the market, and living with it — with search and an evidence-strength filter on top.
See it →Branded preview cards on every page
Shared links now show a proper, on-brand preview card instead of a blank — so the grade and the honest framing travel with the link.
New women's-health pages in review before publishing
Deep, graded hubs on GLP-1s in PCOS and in menopause are drafted and going through medical, legal, and fact-checking review before they publish — we hold health pages until that review clears.
Fourteen free, private tools
Shipped an on-device toolkit — Claim Checker, Side-Effect Journal, Coverage Checker, What-to-Expect, Protein/Fiber/Water planner, Visit-Agenda builder, and more. Everything runs in your browser and stores nothing on our servers.
See it →Full evidence & currency review
We re-checked every page against the latest randomized trials, FDA labels, and regulatory changes, refreshed the numbers where the science had moved, and updated each page's 'last reviewed' date so you can see how current it is.
See it →The Evidence Library launched
Plain-language, evidence-graded answers to the questions people actually ask about GLP-1 medicines — each ranked on the 8-rung Evidence Ladder, with the primary sources linked underneath and nothing to sell but a book.
See it →
Older changes predate this log. For the latest developments in GLP-1 science and regulation (as opposed to changes to this site), see What’s new.